Gujarat Research Allopathic Foundation Laboratories Pvt. Ltd (GRAF) is all set to expand its operations in the four southern states of India with the launch of its Specialty, Diabetes, Cardiology, Gastroenterology and Orthopedics products in the region. The Pharma division of the Ahmedabad-based entity already promotes Anti-Infectives, Pain management and Nutraceutical products in the state of Karnataka, which turns out to be very important market for the company with contribution of about 25% in the total sales revenue.
"Making inroads into the south Indian pharmaceutical market holds significance for us, since it accounts for about 29% of the overall Indian market. Apart from that, Bangalore, being the IT & BT capital of the country, is one of the fastest growing cities and incidence of some lifestyle diseases like diabetes, hypertension and gastro intestinal disorders is also expected to increase with similar space. In such a scenario, some products offered by GRAF such as Probiflora, the only 7 million spores Probiotic meant for a healthy GI system and the complete range of diabetes and hypertension medicines have a good potential in this market. The company expects that about 25% of the total sales will be generated from the four southern states," said, Mr. Shivender Aggarwal, CEO GRAF.
Having its base in Gujarat and with two state-of-the-art facilities - one in Himachal Pradesh & other one in Ahmedabad, GRAF has emerged as a significant global player in the field of manufacturing and marketing of the branded formulations particularly for various therapeutic segments. Not only in the domestic market, but the Rs. 200-crore entity has left extensive footprint in global markets such as ASEAN, AFRO-MENA ,LATUM countries just within ten years after inception and the wellness division of the company is already charged up for a foray into the US, Canadian, European, Japanese, Korean, Australasian and African marketplaces. While over 1,300 dedicated employees and a robust network of over 1500 distributors are the backbone of the company, prime focus on F&D activity and commitment to quality are its core strength.
GRAF offers a wide range of products for almost all of the therapeutic segments such as anti-infectives, cardio-metabolic, gastroenterology, orthopedics, pain management, diabetology and nutraceuticals. Products offered by its wellness division include nutraceuticals, herbal nutrition, OTC and & other pharmaceuticals products.
Company's plant in Ahmedabad, spread over an area of 25 acres, has a 1,40,000 square feet facility with a dedicated 50,000 square feet cephalosporin unit. Both of the manufacturing units are capable of producing products compliant to internationals standards like WHO, ANVISA, MHRA, EU and USFDA. With plans for expansion afoot, the company is also in the process of getting accreditation from TGA, MCC and USFDA.
"Making inroads into the south Indian pharmaceutical market holds significance for us, since it accounts for about 29% of the overall Indian market. Apart from that, Bangalore, being the IT & BT capital of the country, is one of the fastest growing cities and incidence of some lifestyle diseases like diabetes, hypertension and gastro intestinal disorders is also expected to increase with similar space. In such a scenario, some products offered by GRAF such as Probiflora, the only 7 million spores Probiotic meant for a healthy GI system and the complete range of diabetes and hypertension medicines have a good potential in this market. The company expects that about 25% of the total sales will be generated from the four southern states," said, Mr. Shivender Aggarwal, CEO GRAF.
Having its base in Gujarat and with two state-of-the-art facilities - one in Himachal Pradesh & other one in Ahmedabad, GRAF has emerged as a significant global player in the field of manufacturing and marketing of the branded formulations particularly for various therapeutic segments. Not only in the domestic market, but the Rs. 200-crore entity has left extensive footprint in global markets such as ASEAN, AFRO-MENA ,LATUM countries just within ten years after inception and the wellness division of the company is already charged up for a foray into the US, Canadian, European, Japanese, Korean, Australasian and African marketplaces. While over 1,300 dedicated employees and a robust network of over 1500 distributors are the backbone of the company, prime focus on F&D activity and commitment to quality are its core strength.
GRAF offers a wide range of products for almost all of the therapeutic segments such as anti-infectives, cardio-metabolic, gastroenterology, orthopedics, pain management, diabetology and nutraceuticals. Products offered by its wellness division include nutraceuticals, herbal nutrition, OTC and & other pharmaceuticals products.
Company's plant in Ahmedabad, spread over an area of 25 acres, has a 1,40,000 square feet facility with a dedicated 50,000 square feet cephalosporin unit. Both of the manufacturing units are capable of producing products compliant to internationals standards like WHO, ANVISA, MHRA, EU and USFDA. With plans for expansion afoot, the company is also in the process of getting accreditation from TGA, MCC and USFDA.
